Cargando…
Thiazolidinediones are associated with a reduced risk of COPD exacerbations
BACKGROUND: Thiazolidinediones (TZDs) are oral antihyperglycemic medications that are selective agonists to peroxisome proliferator-activated receptor gamma and have been shown to have potent anti-inflammatory effects in the lung. OBJECTIVE: The purpose of this study was to assess whether exposure t...
Autores principales: | Rinne, Seppo T, Liu, Chuan-Fen, Feemster, Laura C, Collins, Bridget F, Bryson, Christopher L, O’Riordan, Thomas G, Au, David H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536761/ https://www.ncbi.nlm.nih.gov/pubmed/26300638 http://dx.doi.org/10.2147/COPD.S82643 |
Ejemplares similares
-
Thiazolidinediones and the risk of asthma exacerbation among patients with diabetes: a cohort study
por: Rinne, Seppo T, et al.
Publicado: (2014) -
Risk of Fracture with Thiazolidinediones: Disease or Drugs?
por: Bazelier, Marloes T., et al.
Publicado: (2012) -
Combination therapies with thiazolidinediones are associated with a lower risk of acute exacerbations in new-onset COPD patients with advanced diabetic mellitus: a cohort-based case–control study
por: Chen, Kuan-Yuan, et al.
Publicado: (2021) -
Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial
por: Beeh, Kai M, et al.
Publicado: (2013) -
Statin Use and the Risk of Subsequent Hospitalized Exacerbations in COPD Patients with Frequent Exacerbations
por: Lin, Chieh-Mo, et al.
Publicado: (2020)